Developer docs
API playgroundTry for free, no card

Search company profiles

Rarelab

Full company profile

uuid00vnp37

Namestring
Rarelab
Legal namestring
Rarelab s.r.l.
Websiteurl
rarelab.eu
Company typeenum
Private
Founded yearint
2010
Descriptiontext

Rarelab S.r.l. is an Italian strategic consulting firm headquartered in Rome that operates exclusively in the rare disease sector. Founded in 2010 by Ilaria Ciancaleoni Bartoli (now President, with Francesco Macchia as Managing Director), the firm employs roughly 20 professionals with 10+ years of domain experience and serves three primary client segments: patient associations (200+ supported), pharmaceutical companies (50+ partnered, 300+ projects delivered), and Italian/European institutions. Service lines span Communication, Patient Advocacy, Public Affairs, Market Access, and Editorial/Publishing, delivered both digitally and in-person.

The firm's underlying platform is a portfolio of specialized media and research assets. These include OMaR Osservatorio Malattie Rare (founded 2010, the first Italian/European press agency dedicated to rare diseases and rare tumors, HON Code certified with 160,000 monthly unique visits as of April 2020), OTA Osservatorio Terapie Avanzate (2019, advanced therapies think tank covering gene therapy, cell therapy, CRISPR, and CAR-T), OSSFOR Osservatorio Farmaci Orfani (2016, orphan drug research center co-founded with CREA Sanità), OSN Osservatorio Screening Neonatale (2018, neonatal screening portal), and Sperimentazionicliniche.it (2018, including the Clinical Map service translating ~45,000 clinical trials terms into Italian). Distribution is reinforced by recurring event properties (Premio OMaR annual awards since 2012, AT2 science-shows since 2019, retreAT policy shaping initiative) and digital content (podcast Reshape, The RareSide social talk series).

Rarelab's revenue model is professional services: project-based and multi-year consulting engagements with pharmaceutical enterprises, advocacy support contracts with patient associations, and policy/institutional work for government bodies. Pricing is not publicly disclosed. The firm operates primarily in Italy with staff distributed across Rome, Padua, Milan, Perugia, and Cagliari, and is founder-owned with no identified external investors, funding rounds, or parent company. Notable institutional relationships include Fondazione Telethon, CREA Sanità, SIMMESN, Rete MetabERN, and the Alleanza Malattie Rare (AMR) permanent technical table established at the Italian Chamber of Deputies in 2017.

Short descriptiontext

Rarelab is an Italian strategic consulting firm specializing in rare diseases, serving patient associations, pharmaceutical companies, and institutions through communication, patient advocacy, market access, public affairs, and publishing services anchored by five specialized observatories.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersRome, Italy
HQ citystring
Rome
HQ countrystring
Italy
HQ regionstring
Europe
Markets served

Serves global market

Offices6 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
rare disease consulting, patient advocacy services, pharmaceutical communications, market access consulting, healthcare public affairs
Industry1 code
PRIMARYBPAGACAM
Rare Disease & Special Needs Support Organizations
NAICS code4 codes
  • Public Relations Agencies541820
  • All Other Professional, Scientific, and Technical Services54199
  • Scientific Research and Development Services5417
  • Business Associations813910
SIC code4 codes
  • Services-Health Services8000
  • Services-Misc Health & Allied Services, Nec8090
  • Miscellaneous Publishing2741
  • Services-Membership Organizations8600
Product category
Healthcare Communications Consulting
No data
GTM motion3 records

Each record includes

Type, Description, Source

Revenue model3 records
1Strategic Consulting Services
TypeProfessional Services
Description

RareLab provides strategic consulting services in Communication, Publishing, Market Access, Patient Advocacy, and Public Affairs to patient associations, pharmaceutical companies, and institutions. Services are delivered digitally and in-person.

rarelab.eu
2Publishing and Editorial Services
TypeProfessional Services
Description

Publishing services including specialized journalism, newsletters on demand, corporate communication products, and public information content for entities, associations, and media operators.

rarelab.eu
3Events and Webinars
TypeProfessional Services
Description

Organization of professional events, conferences, webinars, and training courses for healthcare stakeholders, pharmaceutical companies, and patient associations.

rarelab.eu
Marketing channels9 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels3 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components4 values
Personnel, Operations, Marketing or Sales, Technology or R&D
Pricing details1 tier
1Custom consulting engagements for pharmaceutical companies
ModelOtherBilling cadenceMulti-year contract
Notes

Project-based consulting services; no public pricing available

rarelab.eu
GTM typeB2B
B2B
Offering typeServices
Services
Core offering1 text field

RareLab is a strategic consulting company dedicated to rare diseases, providing Communication, Publishing, Patient Advocacy, Market Access, and Public Affairs services to patient associations, pharmaceutical companies, and Italian/European institutions. The firm also publishes specialized news platforms (OMaR, OTA, OSSFOR, OSN, Sperimentazionicliniche.it), runs the annual Premio OMaR award, and organizes events such as AT2 and retreAT, operating as a 'laboratory of ideas' in the rare disease ecosystem.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 4 values shown
  • 300+ projects completed for pharmaceutical companies
+3 more records
Product overview1 text field

RareLab is a strategic consulting company dedicated to rare diseases, operating as a 'laboratory of ideas' that offers services in Communication, Publishing, Events, Patient Advocacy, Market Access, and Public Affairs. The company publishes multiple specialized news outlets including OMaR Osservatorio Malattie Rare (founded 2010, first Italian press agency for rare diseases), OTA Osservatorio Terapie Avanzate (2019, advanced therapies think tank), OSSFOR Osservatorio Farmaci Orfani (2016, orphan drugs research center), OSN Osservatorio Screening Neonatale (2018, neonatal screening portal), and Sperimentazionicliniche.it (2018, clinical trials portal). These publications are complemented by consulting services targeting Patient Associations, Institutions, and Pharmaceutical Companies, along with events like Premio OMaR (communication award) and AT2 (science-show on advanced therapies).

Product and service16 records
1OMaR Osservatorio Malattie Rare
CategorySpecialized Publication
Description

First and only Italian press agency dedicated to rare diseases and rare tumors; provides free, scientifically correct information on rare diseases to patients, physicians, and public decision-makers.

2OTA Osservatorio Terapie Avanzate
CategorySpecialized Publication
Description

Independent journalism news outlet and think tank dedicated to advanced therapies (gene therapy, cell therapy, CRISPR editing, CAR-T); produces scientifically accurate, fake-free information on innovative treatments.

3OSSFOR Osservatorio Farmaci Orfani
CategoryResearch Center / Think Tank
Description

First permanent research center and think tank entirely dedicated to rare diseases and orphan drugs; publishes annual reports and quaderns on governance and sustainability of rare disease treatments.

4OSN Osservatorio Screening Neonatale
CategorySpecialized Publication
Description

Online journalism portal dedicated to neonatal screening programs; provides free, scientifically accurate information in Italian about neonatal screening and rare diseases it can diagnose.

5Sperimentazionicliniche.it
CategorySpecialized Portal
Description

Journalism portal dedicated to clinical research in Italy offering news and the Clinical Map service—a free search engine allowing Italian users to search clinicaltrials.gov in Italian with approximately 45,000 translated search terms.

6RareLab Communication Services
CategoryConsulting Service
Description

Strategic consulting including content production, media relations, brand identity creation, digital campaigns, video production, press office, social media marketing, and event organization for rare disease stakeholders.

7RareLab Patient Advocacy Services
CategoryConsulting Service
Description

Strategic advocacy services to increase rare disease patients' public representation capacity and weight in decision-making processes through customized advocacy strategies.

8RareLab Public Affairs Services
CategoryConsulting Service
Description

Political-institutional analysis, legislative monitoring, stakeholder mapping, policy analysis, institutional accreditation, partnership building, and lobbying services to transform words into regulatory acts.

9RareLab Market Access Services
CategoryConsulting Service
Description

Strategic consulting integrating traditional market access and public affairs activities with patient empowerment and communication to accelerate access to new therapies.

10RareLab Editorial Services
CategoryConsulting Service
Description

Journalistic and editorial content production both online and offline, including publications, guides, white papers, and specialized medical journalism for rare disease stakeholders.

11RareLab Digital Services
CategoryConsulting Service
Description

Digital formats including patient-doctor meetings, expert Q&A, clinical-stakeholder boards, webinars, media tutorials, distance learning (FAD), and virtual encounters.

12Premio OMaR
CategoryEvent / Award Program
Description

Annual award for communication on rare diseases and rare tumors; recognizes journalists, patient associations, and communication campaigns.

13Reshape Podcast
CategoryMedia Product
Description

First Italian podcast entirely dedicated to advanced therapies and technological innovations transforming healthcare.

14Advanced Talks on Advanced Therapies (AT2)
CategoryEvent Program
Description

Science-show format where advanced therapy experts discuss promises and challenges of innovative therapies.

15retreAT
CategoryEvent Program
Description

Policy shaping project on advanced therapies sustainability, developed over 18 months with five thematic tables culminating in a two-day event in Rome.

16Sportello Legale OMaR
CategoryPatient Service
Description

Legal helpdesk service providing personalized legal consultations to rare disease patients.

Scale indicator8 records

Each record includes

Type, Value, Description, Source

Partnership10 partners
Strategic tierCoreTypeStrategic or Co-development Partner
Description

Fondazione Telethon provides patronage to Osservatorio Terapie Avanzate OTA and supports their initiatives including AT2 events and podcast Reshape. Represents a key partnership for scientific credibility and reach in the advanced therapies field.

2CREA Sanità
Strategic tierCoreTypeStrategic or Co-development Partner
Description

CREA Sanità (Centro per la Ricerca Economica Applicata in Sanità) co-founded OSSFOR with OMaR in 2016, providing research and economic analysis expertise for the think tank on orphan drugs.

rarelab.eu
Strategic tierCoreTypeStrategic or Co-development Partner
Description

Italian Society for the Study of Metabolic Hereditary Diseases and Screening, co-promoter of Osservatorio Screening Neonatale OSN project launched in 2018.

4Rete MetabERN
Strategic tierCoreTypeStrategic or Co-development Partner
Description

European Reference Network for metabolic diseases, partner in Osservatorio Screening Neonatale OSN project.

rarelab.eu
5Giulio D'Alfonso
Strategic tierMinorTypeStrategic or Co-development Partner
Description

Co-initiator of sperimentazionicliniche.it portal launched in 2018 along with Ilaria Ciancaleoni Bartoli and Francesco Macchia.

rarelab.eu
6Ospedale Pediatrico Bambino Gesù
Strategic tierMinorTypeStrategic or Co-development Partner
Description

Pediatric hospital partner for The RareSide 2022 social talk campaign, contributing to awareness initiatives.

rarelab.eu
Strategic tierMinorTypeStrategic or Co-development Partner
Description

Patient organization partner for The RareSide 2022 campaign, representing muscular dystrophy patients.

8Uno Sguardo Raro - Rare Disease International Film Festival
Strategic tierMinorTypeStrategic or Co-development Partner
Description

Film festival partner for The RareSide 2022 campaign, promoting rare disease awareness through visual arts.

rarelab.eu
Strategic tierMinorTypeStrategic or Co-development Partner
Description

Italian Federation of Public Relations provides patronage for The RareSide social talk campaign.

10Alleanza Malattie Rare AMR
Strategic tierCoreTypeStrategic or Co-development Partner
Description

Technical permanent table established July 4, 2017 at Chamber of Deputies, including 90+ patient associations coordinated by OSSFOR for policy advocacy.

rarelab.eu
Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight5 records

Each record includes

Type, Description

Peers10 records
TypeBroad incumbent
Description

Global health communications and advertising agency with patient engagement, PR, and public affairs practices serving pharma. Competes with RareLab for pharma engagement and patient advocacy budgets at international scale.

TypeBroad incumbent
Description

Global healthcare communications network offering creative, medical, and patient engagement services to pharma. Comparable as a broad incumbent serving the same pharma clients on market access and patient advocacy work.

TypeBroad incumbent
Description

Global health communications network offering medical affairs, patient engagement, and public relations to pharma. Comparable because it addresses the same pharma communications, patient advocacy, and policy shaping needs, though at much larger enterprise scale.

TypeEmerging player
Description

Major medical news and professional education platform serving clinicians and pharma. Comparable to OMaR and OTA as a specialized medical journalism and information platform, but at global scale rather than Italian rare disease niche.

TypeBroad incumbent
Description

Global health communications network offering public relations, medical education, and patient engagement services to pharma. Comparable because it competes head-to-head with RareLab for pharma market access and patient advocacy mandates, although at global scale rather than Italian rare disease niche.

TypeBroad incumbent
Description

Global communications agency with strong public affairs and health practice. Comparable as a competitor for pharma public affairs, market access, and patient advocacy engagements, especially on policy-shaping work.

TypeBroad incumbent
Description

International PR and communications agency with a dedicated health practice serving pharma and biotech on patient engagement, market access, and corporate communications. Comparable as a global competitor for the same pharma communications and advocacy business.

8Springer Healthcare
TypeDirect peer
Description

Medical communications and publishing business within Springer Nature, offering pharma services in medical affairs, publications, and patient engagement. Comparable because it overlaps with RareLab's combination of medical publishing, pharma communications, and patient-focused content.

TypeOthers
Description

European Organisation for Rare Diseases, a non-governmental alliance representing 1,000+ rare disease patient associations across Europe. Comparable because it operates in the same rare disease patient advocacy and policy-shaping space as RareLab's AMR Alleanza, though as a non-profit rather than a for-profit consulting firm.

TypeBroad incumbent
Description

Global PR firm with significant health and rare disease practice serving pharma in policy, communications, and patient advocacy. Comparable because it offers the same combined communication + public affairs + market access bundle to large pharma clients, though at much broader scale.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat5 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights6 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers21 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment3 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile3 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
No
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature5 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles6 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

Subsidiaries6 records

Each record includes

Name, Acquired on, Relationship type, Type, Business focus

Compliance1 record

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Rarelab

Healthcare Communications Consultingrarelab.eu

Rarelab is an Italian strategic consulting firm specializing in rare diseases, serving patient associations, pharmaceutical companies, and institutions through communication, patient advocacy, market access, public affairs, and publishing services anchored by five specialized observatories.

What Rarelab does

Rarelab S.r.l. is an Italian strategic consulting firm headquartered in Rome that operates exclusively in the rare disease sector. Founded in 2010 by Ilaria Ciancaleoni Bartoli (now President, with Francesco Macchia as Managing Director), the firm employs roughly 20 professionals with 10+ years of domain experience and serves three primary client segments: patient associations (200+ supported), pharmaceutical companies (50+ partnered, 300+ projects delivered), and Italian/European institutions. Service lines span Communication, Patient Advocacy, Public Affairs, Market Access, and Editorial/Publishing, delivered both digitally and in-person.

The firm's underlying platform is a portfolio of specialized media and research assets. These include OMaR Osservatorio Malattie Rare (founded 2010, the first Italian/European press agency dedicated to rare diseases and rare tumors, HON Code certified with 160,000 monthly unique visits as of April 2020), OTA Osservatorio Terapie Avanzate (2019, advanced therapies think tank covering gene therapy, cell therapy, CRISPR, and CAR-T), OSSFOR Osservatorio Farmaci Orfani (2016, orphan drug research center co-founded with CREA Sanità), OSN Osservatorio Screening Neonatale (2018, neonatal screening portal), and Sperimentazionicliniche.it (2018, including the Clinical Map service translating ~45,000 clinical trials terms into Italian). Distribution is reinforced by recurring event properties (Premio OMaR annual awards since 2012, AT2 science-shows since 2019, retreAT policy shaping initiative) and digital content (podcast Reshape, The RareSide social talk series).

Rarelab's revenue model is professional services: project-based and multi-year consulting engagements with pharmaceutical enterprises, advocacy support contracts with patient associations, and policy/institutional work for government bodies. Pricing is not publicly disclosed. The firm operates primarily in Italy with staff distributed across Rome, Padua, Milan, Perugia, and Cagliari, and is founder-owned with no identified external investors, funding rounds, or parent company. Notable institutional relationships include Fondazione Telethon, CREA Sanità, SIMMESN, Rete MetabERN, and the Alleanza Malattie Rare (AMR) permanent technical table established at the Italian Chamber of Deputies in 2017.

Rarelab firmographics

Firmographics
Name
Rarelab
Legal name
Rarelab s.r.l.
Website
https://rarelab.eu
Company type
Private
Founded year
2010
Operating status
Operating
Headcount range
11–50 employees
Short description
Rarelab is an Italian strategic consulting firm specializing in rare diseases, serving patient associations, pharmaceutical companies, and institutions through communication, patient advocacy, market access, public affairs, and publishing services anchored by five specialized observatories.
Ownership category
akta.pro rank

Rarelab industry classification

Industry
Product category
Healthcare Communications Consulting
NAICS
Public Relations Agencies (541820), All Other Professional, Scientific, and Technical Services (54199), Scientific Research and Development Services (5417), Business Associations (813910)
SIC
Services-Health Services (8000), Services-Misc Health & Allied Services, Nec (8090), Miscellaneous Publishing (2741), Services-Membership Organizations (8600)
akta.pro industry
PRIMARYBPAGACAM
Rare Disease & Special Needs Support Organizations

Keywords

  • Rare disease consulting
  • Patient advocacy services
  • Pharmaceutical communications
  • Market access consulting
  • Healthcare public affairs

Where Rarelab is headquartered

Location

Headquarters

HQ city
Rome
HQ country
Italy
HQ region
Europe

Offices6 records

Markets served

Rarelab business model

Business model
GTM type
B2B
Offering type
Services
Cost components
Personnel, Operations, Marketing or Sales, Technology or R&D

Revenue model

  1. Strategic Consulting Services: RareLab provides strategic consulting services in Communication, Publishing, Market Access, Patient Advocacy, and Public Affairs to patient associations, pharmaceutical companies, and institutions. Services are delivered digitally and in-person.
  2. Publishing and Editorial Services: Publishing services including specialized journalism, newsletters on demand, corporate communication products, and public information content for entities, associations, and media operators.
  3. Events and Webinars: Organization of professional events, conferences, webinars, and training courses for healthcare stakeholders, pharmaceutical companies, and patient associations.

Pricing tiers

ModelBillingPrice
OtherMulti-year contractCustom consulting engagements for pharmaceutical companies

Go-to-market motion3 records

Distribution channels3 records

Marketing channels9 records

Rarelab product offering

Product offering

Core offering

RareLab is a strategic consulting company dedicated to rare diseases, providing Communication, Publishing, Patient Advocacy, Market Access, and Public Affairs services to patient associations, pharmaceutical companies, and Italian/European institutions. The firm also publishes specialized news platforms (OMaR, OTA, OSSFOR, OSN, Sperimentazionicliniche.it), runs the annual Premio OMaR award, and organizes events such as AT2 and retreAT, operating as a 'laboratory of ideas' in the rare disease ecosystem.

Product overview

RareLab is a strategic consulting company dedicated to rare diseases, operating as a 'laboratory of ideas' that offers services in Communication, Publishing, Events, Patient Advocacy, Market Access, and Public Affairs. The company publishes multiple specialized news outlets including OMaR Osservatorio Malattie Rare (founded 2010, first Italian press agency for rare diseases), OTA Osservatorio Terapie Avanzate (2019, advanced therapies think tank), OSSFOR Osservatorio Farmaci Orfani (2016, orphan drugs research center), OSN Osservatorio Screening Neonatale (2018, neonatal screening portal), and Sperimentazionicliniche.it (2018, clinical trials portal). These publications are complemented by consulting services targeting Patient Associations, Institutions, and Pharmaceutical Companies, along with events like Premio OMaR (communication award) and AT2 (science-show on advanced therapies).

Differentiator

Problem solved

Functional benefit

Products and services

  • OMaR Osservatorio Malattie Rare First and only Italian press agency dedicated to rare diseases and rare tumors; provides free, scientifically correct information on rare diseases to patients, physicians, and public decision-makers.
  • OTA Osservatorio Terapie Avanzate Independent journalism news outlet and think tank dedicated to advanced therapies (gene therapy, cell therapy, CRISPR editing, CAR-T); produces scientifically accurate, fake-free information on innovative treatments.
  • OSSFOR Osservatorio Farmaci Orfani First permanent research center and think tank entirely dedicated to rare diseases and orphan drugs; publishes annual reports and quaderns on governance and sustainability of rare disease treatments.
  • OSN Osservatorio Screening Neonatale Online journalism portal dedicated to neonatal screening programs; provides free, scientifically accurate information in Italian about neonatal screening and rare diseases it can diagnose.
  • Sperimentazionicliniche.it Journalism portal dedicated to clinical research in Italy offering news and the Clinical Map service—a free search engine allowing Italian users to search clinicaltrials.gov in Italian with approximately 45,000 translated search terms.
  • RareLab Communication Services Strategic consulting including content production, media relations, brand identity creation, digital campaigns, video production, press office, social media marketing, and event organization for rare disease stakeholders.
  • RareLab Patient Advocacy Services Strategic advocacy services to increase rare disease patients' public representation capacity and weight in decision-making processes through customized advocacy strategies.
  • RareLab Public Affairs Services Political-institutional analysis, legislative monitoring, stakeholder mapping, policy analysis, institutional accreditation, partnership building, and lobbying services to transform words into regulatory acts.
  • RareLab Market Access Services Strategic consulting integrating traditional market access and public affairs activities with patient empowerment and communication to accelerate access to new therapies.
  • RareLab Editorial Services Journalistic and editorial content production both online and offline, including publications, guides, white papers, and specialized medical journalism for rare disease stakeholders.
  • RareLab Digital Services Digital formats including patient-doctor meetings, expert Q&A, clinical-stakeholder boards, webinars, media tutorials, distance learning (FAD), and virtual encounters.
  • Premio OMaR Annual award for communication on rare diseases and rare tumors; recognizes journalists, patient associations, and communication campaigns.
  • Reshape Podcast First Italian podcast entirely dedicated to advanced therapies and technological innovations transforming healthcare.
  • Advanced Talks on Advanced Therapies (AT2) Science-show format where advanced therapy experts discuss promises and challenges of innovative therapies.
  • retreAT Policy shaping project on advanced therapies sustainability, developed over 18 months with five thematic tables culminating in a two-day event in Rome.
  • Sportello Legale OMaR Legal helpdesk service providing personalized legal consultations to rare disease patients.

Quantifiable outcome

  • 300+ projects completed for pharmaceutical companies
  • +3 more outcomes

Companies that use Rarelab

Customer profile

Named customers21 records

Segments3 records

Ideal customer profiles3 records

Rarelab technology and API

Technology

Technology focussed No

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature5 records

Rarelab partnerships and signals

Strategic signal

Partnerships

Ten partnerships are on record, tiered core and minor.

  • Fondazione TelethoncoreStrategic or Co-development PartnerFondazione Telethon provides patronage to Osservatorio Terapie Avanzate OTA and supports their initiatives including AT2 events and podcast Reshape. Represents a key partnership for scientific credibility and reach in the advanced therapies field.
  • CREA SanitàcoreStrategic or Co-development PartnerCREA Sanità (Centro per la Ricerca Economica Applicata in Sanità) co-founded OSSFOR with OMaR in 2016, providing research and economic analysis expertise for the think tank on orphan drugs.
  • SIMMESNcoreStrategic or Co-development PartnerItalian Society for the Study of Metabolic Hereditary Diseases and Screening, co-promoter of Osservatorio Screening Neonatale OSN project launched in 2018.
  • Rete MetabERNcoreStrategic or Co-development PartnerEuropean Reference Network for metabolic diseases, partner in Osservatorio Screening Neonatale OSN project.
  • Giulio D'AlfonsominorStrategic or Co-development PartnerCo-initiator of sperimentazionicliniche.it portal launched in 2018 along with Ilaria Ciancaleoni Bartoli and Francesco Macchia.
  • Ospedale Pediatrico Bambino GesùminorStrategic or Co-development PartnerPediatric hospital partner for The RareSide 2022 social talk campaign, contributing to awareness initiatives.
  • UILDM Unione Italiana Lotta alla Distrofia MuscolareminorStrategic or Co-development PartnerPatient organization partner for The RareSide 2022 campaign, representing muscular dystrophy patients.
  • Uno Sguardo Raro - Rare Disease International Film FestivalminorStrategic or Co-development PartnerFilm festival partner for The RareSide 2022 campaign, promoting rare disease awareness through visual arts.
  • FERPI Federazione Relazioni Pubbliche ItalianaminorStrategic or Co-development PartnerItalian Federation of Public Relations provides patronage for The RareSide social talk campaign.
  • Alleanza Malattie Rare AMRcoreStrategic or Co-development PartnerTechnical permanent table established July 4, 2017 at Chamber of Deputies, including 90+ patient associations coordinated by OSSFOR for policy advocacy.

Scale indicators8 records

Recent moves6 records

Expansion highlights5 records

Rarelab competitors and assessment

Company assessment

Broad incumbents

  • Ogilvy Health: Global health communications and advertising agency with patient engagement, PR, and public affairs practices serving pharma. Competes with RareLab for pharma engagement and patient advocacy budgets at international scale.
  • McCann Health: Global healthcare communications network offering creative, medical, and patient engagement services to pharma. Comparable as a broad incumbent serving the same pharma clients on market access and patient advocacy work.
  • Publicis Health: Global health communications network offering medical affairs, patient engagement, and public relations to pharma. Comparable because it addresses the same pharma communications, patient advocacy, and policy shaping needs, though at much larger enterprise scale.
  • Havas Health & You: Global health communications network offering public relations, medical education, and patient engagement services to pharma. Comparable because it competes head-to-head with RareLab for pharma market access and patient advocacy mandates, although at global scale rather than Italian rare disease niche.
  • BCW (Burson Cohn & Wolfe): Global communications agency with strong public affairs and health practice. Comparable as a competitor for pharma public affairs, market access, and patient advocacy engagements, especially on policy-shaping work.
  • Weber Shandwick (Health): International PR and communications agency with a dedicated health practice serving pharma and biotech on patient engagement, market access, and corporate communications. Comparable as a global competitor for the same pharma communications and advocacy business.
  • Edelman (Health): Global PR firm with significant health and rare disease practice serving pharma in policy, communications, and patient advocacy. Comparable because it offers the same combined communication + public affairs + market access bundle to large pharma clients, though at much broader scale.

Emerging players

  • Medscape (WebMD/Medscape): Major medical news and professional education platform serving clinicians and pharma. Comparable to OMaR and OTA as a specialized medical journalism and information platform, but at global scale rather than Italian rare disease niche.

Direct peers

  • Springer Healthcare: Medical communications and publishing business within Springer Nature, offering pharma services in medical affairs, publications, and patient engagement. Comparable because it overlaps with RareLab's combination of medical publishing, pharma communications, and patient-focused content.

Others

  • EURORDIS: European Organisation for Rare Diseases, a non-governmental alliance representing 1,000+ rare disease patient associations across Europe. Comparable because it operates in the same rare disease patient advocacy and policy-shaping space as RareLab's AMR Alleanza, though as a non-profit rather than a for-profit consulting firm.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights6 records

Customer concentration

Rarelab compliance and trust

Trust signal

Compliance1 record

Rarelab financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Rarelab leadership team

Management profile

Number of profiles

Profiles6 records

Rarelab subsidiaries and ownership

Company hierarchy

Subsidiaries6 records

Rarelab funding detail

Funding detail

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Rarelab M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Rarelab

What does Rarelab do?

RareLab is a strategic consulting company dedicated to rare diseases, providing Communication, Publishing, Patient Advocacy, Market Access, and Public Affairs services to patient associations, pharmaceutical companies, and Italian/European institutions. The firm also publishes specialized news platforms (OMaR, OTA, OSSFOR, OSN, Sperimentazionicliniche.it), runs the annual Premio OMaR award, and organizes events such as AT2 and retreAT, operating as a 'laboratory of ideas' in the rare disease ecosystem.

Is Rarelab a public or private company?

Rarelab is a private company. It is classified as founder individual operated bootstrapped and is currently operating.

When was Rarelab founded?

Rarelab was founded in 2010. It employs 11 to 50 people.

Where is Rarelab based?

Rarelab is headquartered in Rome, Italy, in the Europe region.

How does Rarelab make money?

Three revenue lines are on record. Strategic Consulting Services are the primary driver. The others are publishing and Editorial Services and events and Webinars.

Who are Rarelab's main competitors?

Broad incumbents on record are Ogilvy Health, McCann Health, Publicis Health, Havas Health & You, BCW (Burson Cohn & Wolfe), Weber Shandwick (Health) and Edelman (Health). Medscape (WebMD/Medscape) is listed as an emerging player. Springer Healthcare is listed as a direct peer. EURORDIS is listed as an others.

Does Rarelab have an API?

No public API is recorded for Rarelab.

What industry is Rarelab in?

Rarelab's product category is Healthcare Communications Consulting. Its primary akta.pro industry code is BPAGACAM, Rare Disease & Special Needs Support Organizations. Its NAICS code is 541820 and its SIC code is 8000.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales